Breaking News Instant updates and real-time market news.

GMTX

Gemini Therapeutics

$15.60 /

+0.44 (+2.90%)

04:56
03/02/21
03/02
04:56
03/02/21
04:56

Gemini Therapeutics initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Graig Suvannavejh initiated coverage of Gemini Therapeutics with a Buy rating and $20 price target. With no approved therapies for dry age-related macular degeneration, Gemini addresses a significant market opportunity, Suvannavejh tells investors in a research note. The analyst says the top-line Phase 2 data for GEM103 expected in the second half of 2021 provides a "potential catalyst for share inflection."

GMTX Gemini Therapeutics
$15.60 /

+0.44 (+2.90%)

02/16/21 Stifel
Gemini Therapeutics initiated with a Buy at Stifel

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 03:05
04/19/21
04/19
03:05
04/19/21
03:05
$ECON

Economic Data

/

+

Asian Market Update: Most…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
    Hot Stocks
    Fly Intel: Top five weekend stock stories » 20:02
    04/18/21
    04/18
    20:02
    04/18/21
    20:02
    PTON

    Peloton

    $116.17 /

    -3.77 (-3.14%)

    , TSLA

    Tesla

    $739.67 /

    +0.98 (+0.13%)

    , COIN

    Coinbase

    $341.27 /

    +15.78 (+4.85%)

    , T

    AT&T

    $29.95 /

    +0.195 (+0.66%)

    , PETQ

    PetIQ

    $37.06 /

    +0.43 (+1.17%)

    , CHPT

    ChargePoint

    $22.27 /

    -1.61 (-6.74%)

    , ORLY

    O'Reilly Automotive

    $530.48 /

    +8.3 (+1.59%)

    Catch up on the…

    Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The U.S. Consumer Product Safety Commission issued a bulletin on Saturday about the "danger of popular Peloton Tread+ exercise machine after multiple incidents of small children and a pet being injured beneath the machines. The Commission has found that the public health and safety requires this notice to warn the public quickly of the hazard." The warning comes less than a month after Peloton itself released news of a child's death by a Peloton Tread+. The agency is continuing to investigate all known incidents of injury or death related to the Peloton Tread+. To date, CPSC is aware of 39 incidents including one death." Meanwhile, Peloton (PTON) said in a statement that, "The company is troubled by the Consumer Product Safety Commission's unilateral press release about the Peloton Tread+ because it is inaccurate and misleading. There is no reason to stop using the Tread+, as long as all warnings and safety instructions are followed. Children under 16 should never use the Tread+, and Members should keep children, pets, and objects away from the Tread+ at all times. Peloton was shocked and devastated to learn in March that a child died while using the Tread+. Within a day of learning this news, Peloton notified CPSC. While preparing its report to CPSC, Peloton learned through a doctor's report to CPSC's public database that a child had experienced a brain injury. Peloton spoke to the family who reported that and the child is expected to fully recover. Not wanting to delay in notifying Members, on March 18, 2021, Peloton's co-founder and CEO John Foley sent an urgent reminder directly to Tread+ Members to follow the critical warnings and safety instructions that accompany the Tread+, which state that children, pets, and objects should be kept clear of the Tread+ at all times." 2. Two men died after a Tesla (TSLA) vehicle that authorities believe was operating without anyone in the driver's seat crashed into a tree Saturday night north of Houston, The Wall Street Journal's Rebecca Elliott reported. One of the men was in the front passenger's seat and the other was in the back seat of the Tesla, which was traveling at high speed along a curve before it hit a tree around 11:25pm local time, Harris County Precinct 4 Constable Mark Herman said in an interview. 3. Coinbase Global (COIN) issued stock at an ideal moment-the value of the cryptocurrency market has doubled in just the past two months, Bitcoin is booming, and institutional investors are scrambling to get in, Avi Salzman wrote in this week's edition of Barron's. Coinbase is "the real deal," a novel company with competitive advantages that have enabled it to increase market share despite fierce rivals, the author contends. The stock may falter in the next crypto downturn, but its current valuation does not look unreasonable, Salzman said, adding that there is good reason to believe the stock could rise significantly. 4. Legendary and AT&T (T) subsidiary Warner Bros.' "Godzilla vs. Kong" stayed number 1 in its third outing with an estimated $7.7M domestically to hit $80.5M through Sunday. Overseas, the movie grossed another $12.2M for a total of $309.7M and $390.2M worldwide, passing up "Tenet" at $365M. 5. PetIQ (PETQ), ChargePoint Holdings (CHPT), EVgo, Volta, EVbox, O'Reilly Automotive (ORLY) saw positive mentions in this week's edition of Barron's.

    ShowHide Related Items >><<
    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    PTON Peloton
    $116.17 /

    -3.77 (-3.14%)

    PETQ PetIQ
    $37.06 /

    +0.43 (+1.17%)

    ORLY O'Reilly Automotive
    $530.48 /

    +8.3 (+1.59%)

    COIN Coinbase
    $341.27 /

    +15.78 (+4.85%)

    CHPT ChargePoint
    $22.27 /

    -1.61 (-6.74%)

    PTON Peloton
    $116.17 /

    -3.77 (-3.14%)

    04/07/21 KeyBanc
    Peloton Bike OTD times improving further, says KeyBanc
    04/06/21 Credit Suisse
    Peloton initiated with an Outperform at Credit Suisse
    04/05/21 Evercore ISI
    Peloton assumed at In Line from Outperform at Evercore ISI
    03/31/21 Wolfe Research
    Peloton initiated with a Peer Perform at Wolfe Research
    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    04/13/21 Credit Suisse
    Credit Suisse ahead of consensus into Q1 EPS for Tesla
    04/12/21
    Fly Intel: Top five analyst upgrades
    04/12/21 Canaccord
    Canaccord upgrades Tesla with over $1,000 target on 'Apple-esque' ecosystem
    04/12/21 Canaccord
    Tesla upgraded to Buy from Hold at Canaccord
    COIN Coinbase
    $341.27 /

    +15.78 (+4.85%)

    04/15/21 Loop Capital
    Loop Capital starts Coinbase at Buy, sees 'lots of runway before takeoff'
    04/15/21 Loop Capital
    Coinbase initiated with a Buy at Loop Capital
    04/15/21
    Fly Intel: Top five analyst initiations
    04/15/21 DA Davidson
    Coinbase price target raised to $650 from $440 at DA Davidson
    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    03/10/21 RBC Capital
    Fortinet price target raised to $175 from $162 at RBC Capital
    03/10/21 DA Davidson
    Fortinet price target raised to $200 from $180 at DA Davidson
    03/10/21 BTIG
    Fortinet price target raised to $205 from $183 at BTIG
    03/05/21 JPMorgan
    JPMorgan sees AT&T rallying into analyst meeting, but not after
    PETQ PetIQ
    $37.06 /

    +0.43 (+1.17%)

    10/15/20 Jefferies
    PetIQ assumed with a Buy at Jefferies
    08/17/20 Guggenheim
    Zoetis price target raised to $175 from $139 at Guggenheim
    07/01/20 Raymond James
    PetIQ price target raised to $41 from $35 at Raymond James
    06/25/20 Guggenheim
    PetIQ price target raised to $44 from $33.50 at Guggenheim
    CHPT ChargePoint
    $22.27 /

    -1.61 (-6.74%)

    04/16/21
    ChargePoint initiated with Buy, $29 target at R.F. Lafferty
    03/25/21 Citi
    ChargePoint initiated with a Neutral at Citi
    03/08/21 Cowen
    ChargePoint initiated with an Outperform at Cowen
    03/08/21 Cowen
    ChargePoint initiated with an Outperform at Cowen
    ORLY O'Reilly Automotive
    $530.48 /

    +8.3 (+1.59%)

    03/29/21 Wells Fargo
    O'Reilly Automotive price target raised to $575 from $535 at Wells Fargo
    03/26/21 Stephens
    O'Reilly Automotive price target raised to $575, named Best Idea at Stephens
    03/17/21 Wells Fargo
    O'Reilly Automotive price target raised to $535 from $525 at Wells Fargo
    03/17/21 Wells Fargo
    Advance Auto Parts price target raised to $185 from $165 at Wells Fargo
    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    PTON Peloton
    $116.17 /

    -3.77 (-3.14%)

    PETQ PetIQ
    $37.06 /

    +0.43 (+1.17%)

    ORLY O'Reilly Automotive
    $530.48 /

    +8.3 (+1.59%)

    COIN Coinbase
    $341.27 /

    +15.78 (+4.85%)

    CHPT ChargePoint
    $22.27 /

    -1.61 (-6.74%)

    • 14
      Apr
    • 12
      Mar
    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    PTON Peloton
    $116.17 /

    -3.77 (-3.14%)

    PETQ PetIQ
    $37.06 /

    +0.43 (+1.17%)

    ORLY O'Reilly Automotive
    $530.48 /

    +8.3 (+1.59%)

    COIN Coinbase
    $341.27 /

    +15.78 (+4.85%)

    CHPT ChargePoint
    $22.27 /

    -1.61 (-6.74%)

    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    PTON Peloton
    $116.17 /

    -3.77 (-3.14%)

    ORLY O'Reilly Automotive
    $530.48 /

    +8.3 (+1.59%)

    COIN Coinbase
    $341.27 /

    +15.78 (+4.85%)

    CHPT ChargePoint
    $22.27 /

    -1.61 (-6.74%)

    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    PTON Peloton
    $116.17 /

    -3.77 (-3.14%)

    PETQ PetIQ
    $37.06 /

    +0.43 (+1.17%)

    CHPT ChargePoint
    $22.27 /

    -1.61 (-6.74%)

    Periodicals
    Canada's Ontario to expand use of AstraZeneca COVID vaccine, Reuters says » 19:51
    04/18/21
    04/18
    19:51
    04/18/21
    19:51
    AZN

    AstraZeneca

    $50.74 /

    -0.1 (-0.20%)

    The Canadian province of…

    The Canadian province of Ontario will begin offering AstraZeneca's COVID-19 vaccine on Tuesday to people turning 40 or older this year, Reuters' Allison Martell reports, citing a government source. The change will broaden access to vaccines as a third wave of infections threatens to overwhelm hospitals in Canada's most-populous province, and should make it easier to use doses that in some cases have been accumulating at pharmacies, the author adds. Reference Link

    ShowHide Related Items >><<
    AZN AstraZeneca
    $50.74 /

    -0.1 (-0.20%)

    AZN AstraZeneca
    $50.74 /

    -0.1 (-0.20%)

    04/14/21 Guggenheim
    Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
    04/12/21
    Fly Intel: Top five analyst downgrades
    04/12/21 B. Riley
    B. Riley calls Agenus the next Seagen, reiterates $8 target
    04/12/21 Argus
    AstraZeneca downgraded to Hold from Buy at Argus
    AZN AstraZeneca
    $50.74 /

    -0.1 (-0.20%)

    AZN AstraZeneca
    $50.74 /

    -0.1 (-0.20%)

    AZN AstraZeneca
    $50.74 /

    -0.1 (-0.20%)

    AZN AstraZeneca
    $50.74 /

    -0.1 (-0.20%)

    Initiation
    Innoviz Technologies initiated with a Neutral at Goldman Sachs » 19:49
    04/18/21
    04/18
    19:49
    04/18/21
    19:49
    INVZ

    Innoviz Technologies

    $10.13 /

    +0.155 (+1.55%)

    , VLDR

    Velodyne Lidar

    $13.38 /

    +0.25 (+1.90%)

    Goldman Sachs analyst…

    Goldman Sachs analyst Mark Delaney initiated coverage of Innoviz Technologies (INVZ) with a Neutral rating and $11 price target. The analyst says that while his 2021 and 2022 estimates are about in line with the company's guidance, he sees the potential for lower revenue and margins in 2023 through 2025. Competition from both from non-lidar solutions and other lidar companies could limit growth, Delaney tells investors in a research note. His "base case" revenue multiple for Innoviz is lower than Velodyne Lidar (VLDR) given that Velodyne "is already generating material revenue." However, Delaney considers Innoviz to be in the group of industry leaders technically and that it has the potential to generate "enough business momentum to trade materially higher in a bull case and thus merits a similar bull case multiple."

    ShowHide Related Items >><<
    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    INVZ Innoviz Technologies
    $10.13 /

    +0.155 (+1.55%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    04/18/21 Goldman Sachs
    Velodyne Lidar initiated with a Neutral at Goldman Sachs
    03/30/21
    Fly Intel: Top five analyst downgrades
    03/30/21 Craig-Hallum
    Velodyne downgraded to Hold at Craig-Hallum on lack of catalysts, Board drama
    03/30/21 Craig-Hallum
    Velodyne Lidar downgraded to Hold from Buy at Craig-Hallum
    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    INVZ Innoviz Technologies
    $10.13 /

    +0.155 (+1.55%)

    Initiation
    Velodyne Lidar initiated with a Neutral at Goldman Sachs » 19:46
    04/18/21
    04/18
    19:46
    04/18/21
    19:46
    VLDR

    Velodyne Lidar

    $13.38 /

    +0.25 (+1.90%)

    Goldman Sachs analyst…

    Goldman Sachs analyst Mark Delaney initiated coverage of Velodyne Lidar with a Neutral rating and $13 price target. Velodyne is an "early mover in lidar with a broad product portfolio," Delaney tells investors in a research note. The analyst views the company's valuation as "reasonable but full" and expects lower long-term margins. The stock trades near the median of other lidar companies, at a premium to auto tier ones, but at a discount to leading electric vehicle/auto tech companies that have a role in advanced driver assistance systems, says Delaney.

    ShowHide Related Items >><<
    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    03/30/21
    Fly Intel: Top five analyst downgrades
    03/30/21 Craig-Hallum
    Velodyne downgraded to Hold at Craig-Hallum on lack of catalysts, Board drama
    03/30/21 Craig-Hallum
    Velodyne Lidar downgraded to Hold from Buy at Craig-Hallum
    03/24/21 UBS
    Apple recently granted patent for LiDAR system, says UBS
    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    VLDR Velodyne Lidar
    $13.38 /

    +0.25 (+1.90%)

    Upgrade
    PT Indofood CBP upgraded to Buy from Neutral at Goldman Sachs » 19:40
    04/18/21
    04/18
    19:40
    04/18/21
    19:40
    PIFFY

    PT Indofood CBP

    $12.76 /

    + (+0.00%)

    Goldman Sachs analyst…

    Goldman Sachs analyst June Zhu upgraded PT Indofood CBP to Buy from Neutral with a IDR 11,350 price target, implying 27% upside potential. The anlayst expects strong earnings growth to drive the shares and notes that Pinehill's sales growth and profitability are much higher than ICBP's domestic business.

    Downgrade
    OneMain Holdings downgraded to Market Perform from Outperform at BMO Capital » 19:36
    04/18/21
    04/18
    19:36
    04/18/21
    19:36
    OMF

    OneMain Holdings

    $55.96 /

    +0.73 (+1.32%)

    , KKR

    KKR

    $53.29 /

    +0.36 (+0.68%)

    , APO

    Apollo Global

    $51.54 /

    +1.27 (+2.53%)

    , BEN

    Franklin Resources

    $30.05 /

    -0.24 (-0.79%)

    , VCTR

    Victory Capital

    $27.48 /

    -0.25 (-0.90%)

    , MS

    Morgan Stanley

    $78.58 /

    -2.31 (-2.86%)

    , GS

    Goldman Sachs

    $342.30 /

    +3.71 (+1.10%)

    BMO Capital analyst James…

    BMO Capital analyst James Fotheringham downgraded OneMain Holdings (OMF) to Market Perform from Outperform with an unchanged price target of $60. The analyst cites "exclusively" valuation for the downgrade. The shares have tripled over the past year and are now well above historical averages, Fotheringham tells investors in a research note. The analyst notes that he's not making a call on the upcoming quarter. He prefers market-oriented asset managers like KKR (KKR), Apollo Global (APO) , Franklin Resources (BEN), and Victory Capital (VCTR) as well as investment banks Morgan Stanley (MS) and Goldman Sachs (GS).

    ShowHide Related Items >><<
    VCTR Victory Capital
    $27.48 /

    -0.25 (-0.90%)

    OMF OneMain Holdings
    $55.96 /

    +0.73 (+1.32%)

    MS Morgan Stanley
    $78.58 /

    -2.31 (-2.86%)

    KKR KKR
    $53.29 /

    +0.36 (+0.68%)

    GS Goldman Sachs
    $342.30 /

    +3.71 (+1.10%)

    BEN Franklin Resources
    $30.05 /

    -0.24 (-0.79%)

    APO Apollo Global
    $51.54 /

    +1.27 (+2.53%)

    OMF OneMain Holdings
    $55.96 /

    +0.73 (+1.32%)

    04/15/21 JPMorgan
    OneMain Holdings price target lowered to $64 from $65 at JPMorgan
    02/11/21 Piper Sandler
    OneMain secondary creates buying opportunity, says Piper Sandler
    02/10/21 Northland
    OneMain Holdings price target raised to $60 from $45 at Northland
    02/10/21 Citi
    OneMain Holdings price target raised to $62 from $45 at Citi
    KKR KKR
    $53.29 /

    +0.36 (+0.68%)

    04/14/21 BMO Capital
    KKR price target raised to $71 from $69 at BMO Capital
    04/14/21 Credit Suisse
    KKR price target raised to $60 from $53 at Credit Suisse
    04/14/21 Deutsche Bank
    KKR price target raised to $52 from $47 at Deutsche Bank
    04/14/21 Citi
    Citi boosts KKR target to $65, removes from US Focus List
    APO Apollo Global
    $51.54 /

    +1.27 (+2.53%)

    04/14/21
    Fly Intel: Top five analyst upgrades
    04/14/21 Oppenheimer
    Apollo Global upgraded to Outperform at Oppenheimer
    04/14/21 Oppenheimer
    Apollo Global upgraded to Outperform from Perform at Oppenheimer
    04/12/21 Wells Fargo
    Apollo Global price target lowered to $57 from $62 at Wells Fargo
    BEN Franklin Resources
    $30.05 /

    -0.24 (-0.79%)

    04/09/21 Deutsche Bank
    Franklin Resources price target raised to $29 from $26 at Deutsche Bank
    03/29/21 BMO Capital
    Franklin Resources upgraded to Outperform from Market Perform at BMO Capital
    01/28/21
    Invesco upgraded to Buy from Neutral at UBS
    01/25/21 Barclays
    Franklin Resources price target raised to $24 from $21 at Barclays
    VCTR Victory Capital
    $27.48 /

    -0.25 (-0.90%)

    04/09/21 BofA
    Victory Capital double-upgraded to Buy from Underperform at BofA
    04/09/21 BofA
    Victory Capital upgraded to Buy from Underperform at BofA
    11/19/20
    Fly Intel: Top five analyst downgrades
    11/19/20 BofA
    Victory Capital double-downgraded to Underperform from Buy at BofA
    MS Morgan Stanley
    $78.58 /

    -2.31 (-2.86%)

    04/16/21 Wells Fargo
    Wells Fargo 'expected more' from Morgan Stanley after disclosing Archegos loss
    04/09/21 JMP Securities
    Goldman Sachs price target raised to $400 from $338 at JMP Securities
    04/07/21 Barclays
    Morgan Stanley price target raised to $98 from $95 at Barclays
    04/01/21 Deutsche Bank
    Morgan Stanley price target raised to $79 from $68 at Deutsche Bank
    GS Goldman Sachs
    $342.30 /

    +3.71 (+1.10%)

    04/16/21 BMO Capital
    Goldman Sachs price target raised to $432 from $409 at BMO Capital
    04/15/21 DA Davidson
    Goldman Sachs price target raised to $378 from $347 at DA Davidson
    04/15/21 Oppenheimer
    Goldman Sachs price target raised to $497 from $468 at Oppenheimer
    04/15/21 Credit Suisse
    Goldman Sachs price target raised to $400 from $395 at Credit Suisse
    VCTR Victory Capital
    $27.48 /

    -0.25 (-0.90%)

    OMF OneMain Holdings
    $55.96 /

    +0.73 (+1.32%)

    MS Morgan Stanley
    $78.58 /

    -2.31 (-2.86%)

    KKR KKR
    $53.29 /

    +0.36 (+0.68%)

    GS Goldman Sachs
    $342.30 /

    +3.71 (+1.10%)

    BEN Franklin Resources
    $30.05 /

    -0.24 (-0.79%)

    APO Apollo Global
    $51.54 /

    +1.27 (+2.53%)

    • 11
      Feb
    • 11
      Nov
    MS Morgan Stanley
    $78.58 /

    -2.31 (-2.86%)

    KKR KKR
    $53.29 /

    +0.36 (+0.68%)

    GS Goldman Sachs
    $342.30 /

    +3.71 (+1.10%)

    APO Apollo Global
    $51.54 /

    +1.27 (+2.53%)

    MS Morgan Stanley
    $78.58 /

    -2.31 (-2.86%)

    KKR KKR
    $53.29 /

    +0.36 (+0.68%)

    GS Goldman Sachs
    $342.30 /

    +3.71 (+1.10%)

    APO Apollo Global
    $51.54 /

    +1.27 (+2.53%)

    VCTR Victory Capital
    $27.48 /

    -0.25 (-0.90%)

    MS Morgan Stanley
    $78.58 /

    -2.31 (-2.86%)

    GS Goldman Sachs
    $342.30 /

    +3.71 (+1.10%)

    BEN Franklin Resources
    $30.05 /

    -0.24 (-0.79%)

    APO Apollo Global
    $51.54 /

    +1.27 (+2.53%)

    Downgrade
    Discover downgraded to Market Perform from Outperform at BMO Capital » 19:33
    04/18/21
    04/18
    19:33
    04/18/21
    19:33
    DFS

    Discover

    $102.29 /

    +0.3 (+0.29%)

    BMO Capital analyst James…

    BMO Capital analyst James Fotheringham downgraded Discover Financial Services to Market Perform from Outperform with an unchanged price target of $105. The analyst cites "exclusively" valuation for the downgrade. The shares have doubled over the past year and are now at or above historical averages, Fotheringham tells investors in a research note. The analyst notes that he's not making a call on the upcoming quarter.

    ShowHide Related Items >><<
    DFS Discover
    $102.29 /

    +0.3 (+0.29%)

    DFS Discover
    $102.29 /

    +0.3 (+0.29%)

    04/16/21 Piper Sandler
    Discover price target raised to $103 from $97 at Piper Sandler
    04/08/21 Piper Sandler
    Discover price target raised to $97 from $94 at Piper Sandler
    03/17/21 Wedbush
    LendingClub price target raised to $20.50 from $14 at Wedbush
    03/15/21 Wells Fargo
    Discover price target raised to $111 from $105 at Wells Fargo
    DFS Discover
    $102.29 /

    +0.3 (+0.29%)

    DFS Discover
    $102.29 /

    +0.3 (+0.29%)

    DFS Discover
    $102.29 /

    +0.3 (+0.29%)

    Periodicals
    Fauci predicts resumption of J&J COVID vaccine use, Reuters reports » 17:55
    04/18/21
    04/18
    17:55
    04/18/21
    17:55
    JNJ

    Johnson & Johnson

    $162.24 /

    +1.74 (+1.08%)

    Anthony Fauci on Sunday…

    Anthony Fauci on Sunday predicted that U.S. health regulators will end the temporary pause on distributing Johnson & Johnson's COVID-19 vaccine, adding he expects a decision could come as soon as Friday, Reuters' Sarah Lynch reports. The U.S. Centers for Disease Control and Prevention advisory panel is set to meet on April 23 to discuss the next steps for the vaccine. Reference Link

    ShowHide Related Items >><<
    JNJ Johnson & Johnson
    $162.24 /

    +1.74 (+1.08%)

    JNJ Johnson & Johnson
    $162.24 /

    +1.74 (+1.08%)

    04/14/21 Guggenheim
    Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
    04/13/21 Goldman Sachs
    J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
    04/13/21 Morgan Stanley
    Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
    04/13/21 JPMorgan
    Vaccine pause 'incremental negative' for J&J, says JPMorgan
    JNJ Johnson & Johnson
    $162.24 /

    +1.74 (+1.08%)

    JNJ Johnson & Johnson
    $162.24 /

    +1.74 (+1.08%)

    JNJ Johnson & Johnson
    $162.24 /

    +1.74 (+1.08%)

    JNJ Johnson & Johnson
    $162.24 /

    +1.74 (+1.08%)

    Periodicals
    TSMC warns trade tensions may disrupt supply, Bloomberg reports » 17:48
    04/18/21
    04/18
    17:48
    04/18/21
    17:48
    TSM

    TSMC

    $118.84 /

    +0.48 (+0.41%)

    , AAPL

    Apple

    $134.15 /

    -0.34 (-0.25%)

    TSMC (TSM) warned for the…

    TSMC (TSM) warned for the first time that trade tensions may disrupt its access to key production equipment and hit its operations, amid increasing friction between the U.S. and China, Bloomberg's Debby Wu reports. The company, which produces semiconductors for Apple (AAPL) and other major global tech companies, said in its annual report that "ongoing trade tensions or protectionist measures could result in increased prices for, or even unavailability of, key equipment." Reference Link

    ShowHide Related Items >><<
    TSM TSMC
    $118.84 /

    +0.48 (+0.41%)

    AAPL Apple
    $134.15 /

    -0.34 (-0.25%)

    TSM TSMC
    $118.84 /

    +0.48 (+0.41%)

    04/15/21 Argus
    Lam Research price target raised to $725 from $625 at Argus
    04/12/21
    Fly Intel: Top five analyst initiations
    04/12/21 Atlantic Equities
    TSMC initiated with a Neutral at Atlantic Equities
    04/01/21 DA Davidson
    Onto Innovation price target raised to $80 from $75 at DA Davidson
    AAPL Apple
    $134.15 /

    -0.34 (-0.25%)

    04/14/21 Evercore ISI
    Apple added to Tactical Outperform list at Evercore ISI
    04/13/21 Wedbush
    Facebook assumed with Neutral at Wedbush, cites privacy risk
    04/12/21 Canaccord
    Canaccord upgrades Tesla with over $1,000 target on 'Apple-esque' ecosystem
    04/09/21 Citi
    Citi tells investors to focus on Apple's capital deployment, iPhone gains
    TSM TSMC
    $118.84 /

    +0.48 (+0.41%)

    AAPL Apple
    $134.15 /

    -0.34 (-0.25%)

    TSM TSMC
    $118.84 /

    +0.48 (+0.41%)

    AAPL Apple
    $134.15 /

    -0.34 (-0.25%)

    TSM TSMC
    $118.84 /

    +0.48 (+0.41%)

    AAPL Apple
    $134.15 /

    -0.34 (-0.25%)

    TSM TSMC
    $118.84 /

    +0.48 (+0.41%)

    AAPL Apple
    $134.15 /

    -0.34 (-0.25%)

    Periodicals
    Amazon cancels Lord of the Rings game announced two years ago, Bloomberg says » 17:40
    04/18/21
    04/18
    17:40
    04/18/21
    17:40
    AMZN

    Amazon.com

    $3,398.86 /

    +20.63 (+0.61%)

    , TCEHY

    Tencent

    $81.00 /

    +1.02 (+1.28%)

    Amazon's (AMZN)…

    Amazon's (AMZN) embattled video game division has canceled an online role-playing game based on the fantasy series Lord of the Rings, which was announced in 2019, in another setback for the technology giant, Bloomberg's Jason Schreier reports. The game had been in development at Amazon Game Studios alongside the China-based Leyou Technologies. which was purchased by conglomerate Tencent (TCEHY) in December, the author notes. Reference Link

    ShowHide Related Items >><<
    TCEHY Tencent
    $81.00 /

    +1.02 (+1.28%)

    AMZN Amazon.com
    $3,398.86 /

    +20.63 (+0.61%)

    AMZN Amazon.com
    $3,398.86 /

    +20.63 (+0.61%)

    04/13/21 Jefferies
    Amazon sum-of-the-parts supports 'pathway to $5,700,' says Jefferies
    04/12/21 Jefferies
    Microsoft deal emphasizes healthcare cloud focus, says Jefferies
    04/12/21 BMO Capital
    Microsoft price target raised to $280 from $270 at BMO Capital
    04/05/21 Evercore ISI
    Amazon.com assumed with an Outperform at Evercore ISI
    TCEHY Tencent
    $81.00 /

    +1.02 (+1.28%)

    03/22/21 Mizuho
    Tencent price target raised to Rmb 710 from Rmb 600 at Mizuho
    02/16/21 Barclays
    Tencent price target raised to $115 from $89 at Barclays
    01/26/21 KeyBanc
    Tencent downgraded to Sector Weight on valuation at KeyBanc
    01/26/21 KeyBanc
    Tencent downgraded to Sector Weight from Overweight at KeyBanc
    TCEHY Tencent
    $81.00 /

    +1.02 (+1.28%)

    AMZN Amazon.com
    $3,398.86 /

    +20.63 (+0.61%)

    TCEHY Tencent
    $81.00 /

    +1.02 (+1.28%)

    AMZN Amazon.com
    $3,398.86 /

    +20.63 (+0.61%)

    TCEHY Tencent
    $81.00 /

    +1.02 (+1.28%)

    AMZN Amazon.com
    $3,398.86 /

    +20.63 (+0.61%)

    AMZN Amazon.com
    $3,398.86 /

    +20.63 (+0.61%)

    Periodicals
    Japan, Pfizer agree on more vaccine supply, Bloomberg reports » 17:35
    04/18/21
    04/18
    17:35
    04/18/21
    17:35
    PFE

    Pfizer

    $38.57 /

    +0.96 (+2.55%)

    Japan's vaccine czar…

    Japan's vaccine czar Taro Kono said in a Fuji TV program on Sunday that Pfizer will increase supplies of the COVID-19 vaccine for Japan by the end of September, Bloomberg's Chikako Mogi reports. Pfizer's vaccine is currently the only one approved for use in Japan, and the inoculation rollout which started in February has so far been slow, the report notes. Reference Link

    ShowHide Related Items >><<
    PFE Pfizer
    $38.57 /

    +0.96 (+2.55%)

    PFE Pfizer
    $38.57 /

    +0.96 (+2.55%)

    04/13/21 Morgan Stanley
    Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
    04/13/21 JPMorgan
    Vaccine pause 'incremental negative' for J&J, says JPMorgan
    04/09/21
    Pfizer to host conference call
    04/06/21 RBC Capital
    Pfizer transferred with a Sector Perform at RBC Capital
    PFE Pfizer
    $38.57 /

    +0.96 (+2.55%)

    PFE Pfizer
    $38.57 /

    +0.96 (+2.55%)

    PFE Pfizer
    $38.57 /

    +0.96 (+2.55%)

    PFE Pfizer
    $38.57 /

    +0.96 (+2.55%)

    Periodicals
    Tesla crash in Texas believed to be driverless, WSJ reports » 17:31
    04/18/21
    04/18
    17:31
    04/18/21
    17:31
    TSLA

    Tesla

    $739.67 /

    +0.98 (+0.13%)

    Two men died after a…

    Two men died after a Tesla vehicle that authorities believe was operating without anyone in the driver's seat crashed into a tree Saturday night north of Houston, The Wall Street Journal's Rebecca Elliott reports. One of the men was in the front passenger's seat and the other was in the back seat of the Tesla, which was traveling at high speed along a curve before it hit a tree around 11:25pm local time, Harris County Precinct 4 Constable Mark Herman said in an interview. Reference Link

    ShowHide Related Items >><<
    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    04/13/21 Credit Suisse
    Credit Suisse ahead of consensus into Q1 EPS for Tesla
    04/12/21
    Fly Intel: Top five analyst upgrades
    04/12/21 Canaccord
    Canaccord upgrades Tesla with over $1,000 target on 'Apple-esque' ecosystem
    04/12/21 Canaccord
    Tesla upgraded to Buy from Hold at Canaccord
    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    TSLA Tesla
    $739.67 /

    +0.98 (+0.13%)

    Conference/Events
    Evogene to hold a virtual analyst and investor day » 17:24
    04/18/21
    04/18
    17:24
    04/18/21
    17:24
    EVGN

    Evogene

    $4.37 /

    +0.0899 (+2.10%)

    Virtual Analyst and…

    Virtual Analyst and Investor Day to be held on April 21 at 9 am. Webcast Link

    ShowHide Related Items >><<
    EVGN Evogene
    $4.37 /

    +0.0899 (+2.10%)

    EVGN Evogene
    $4.37 /

    +0.0899 (+2.10%)

    11/30/20 Cantor Fitzgerald
    Cantor Fitzgerald starts 'highly underappreciated' Evogene at Overweight
    11/30/20 Cantor Fitzgerald
    Evogene initiated with an Overweight at Cantor Fitzgerald
    EVGN Evogene
    $4.37 /

    +0.0899 (+2.10%)

    On The Fly
    Box Office Battle: 'Godzilla vs. Kong' wins weekend with $7.7M » 17:23
    04/18/21
    04/18
    17:23
    04/18/21
    17:23
    T

    AT&T

    $29.95 /

    +0.195 (+0.66%)

    , CMCSA

    Comcast

    $55.11 /

    +0.97 (+1.79%)

    , CMCSK

    Comcast

    $58.00 /

    + (+0.00%)

    , SNE

    Sony

    /

    +

    , LGF.A

    Lionsgate

    $16.04 /

    +0.105 (+0.66%)

    , LGF.B

    Lionsgate

    $13.68 /

    +0.13 (+0.96%)

    , DIS

    Disney

    $187.28 /

    +1.42 (+0.76%)

    , VIACA

    ViacomCBS

    $44.29 /

    +1.24 (+2.88%)

    , VIAC

    ViacomCBS

    $39.32 /

    +0.11 (+0.28%)

    "Box Office Battle" is…

    ShowHide Related Items >><<
    VIACA ViacomCBS
    $44.29 /

    +1.24 (+2.88%)

    VIAC ViacomCBS
    $39.32 /

    +0.11 (+0.28%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    SNE Sony
    /

    +

    LGF.B Lionsgate
    $13.68 /

    +0.13 (+0.96%)

    LGF.A Lionsgate
    $16.04 /

    +0.105 (+0.66%)

    DIS Disney
    $187.28 /

    +1.42 (+0.76%)

    CMCSK Comcast
    $58.00 /

    + (+0.00%)

    CMCSA Comcast
    $55.11 /

    +0.97 (+1.79%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    03/10/21 RBC Capital
    Fortinet price target raised to $175 from $162 at RBC Capital
    03/10/21 DA Davidson
    Fortinet price target raised to $200 from $180 at DA Davidson
    03/10/21 BTIG
    Fortinet price target raised to $205 from $183 at BTIG
    03/05/21 JPMorgan
    JPMorgan sees AT&T rallying into analyst meeting, but not after
    CMCSA Comcast
    $55.11 /

    +0.97 (+1.79%)

    04/16/21
    Fly Intel: Top five analyst upgrades
    04/16/21 Raymond James
    Comcast upgraded to Outperform from Market Perform at Raymond James
    04/16/21 Raymond James
    Comcast upgraded to Outperform from Market Perform at Raymond James
    04/12/21 Pivotal Research
    Comcast price target raised to $65 from $63 at Pivotal Research
    CMCSK Comcast
    $58.00 /

    + (+0.00%)

    02/23/21 Credit Suisse
    SeaWorld price target raised to $52 from $34 at Credit Suisse
    10/07/20 Benchmark
    Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
    09/22/20 Benchmark
    Comcast price target raised to $60 from $54 at Benchmark
    09/16/20 Pivotal Research
    Comcast price target raised to $60 from $52 at Pivotal Research
    SNE Sony
    /

    +

    04/09/21 Benchmark
    Netflix deal for Sony films 'hardly transformative,' says Benchmark
    03/08/21 Macquarie
    Sony downgraded to Neutral from Outperform at Macquarie
    03/08/21 BofA
    BofA says buy AMD and Nvidia as Steam data points to GPU upgrade tailwinds
    01/12/21 Citi
    Sony PS5 sales to date 'steady but somewhat disappointing,' says Citi
    LGF.A Lionsgate
    $16.04 /

    +0.105 (+0.66%)

    02/08/21 Deutsche Bank
    Lionsgate price target raised to $16 from $12 at Deutsche Bank
    02/05/21 RBC Capital
    Lionsgate price target raised to $13 from $7 at RBC Capital
    01/28/21 Macquarie
    Lionsgate price target raised to $18 from $12 at Macquarie
    LGF.B Lionsgate
    $13.68 /

    +0.13 (+0.96%)

    11/02/20 Morgan Stanley
    Lionsgate assumed with an Equal Weight at Morgan Stanley
    09/02/20 Barrington
    Lionsgate price target raised to $14 from $10 at Barrington
    05/05/20 Canaccord
    Lionsgate price target lowered to $13 from $16 at Canaccord
    DIS Disney
    $187.28 /

    +1.42 (+0.76%)

    04/16/21 Truist
    Disney price target raised to $205 from $195 at Truist
    04/16/21 UBS
    Disney checks show improving backdrop, says UBS
    04/08/21 KeyBanc
    Netflix, Disney superior retention reinforces scale advantages, says KeyBanc
    03/29/21 Loop Capital
    ViacomCBS upgraded to Hold at Loop Capital after share price decline
    VIACA ViacomCBS
    $44.29 /

    +1.24 (+2.88%)

    01/05/21 Gabelli
    ViacomCBS named a best idea for 2021 at Gabelli
    07/13/20
    Fly Intel: Top five analyst initiations
    07/13/20
    Fly Intel: Top five analyst downgrades
    VIAC ViacomCBS
    $39.32 /

    +0.11 (+0.28%)

    04/07/21 Wolfe Research
    Wolfe upgrades ViacomCBS to Outperform, sees 58% share upside
    04/07/21 Wolfe Research
    ViacomCBS upgraded to Outperform from Peer Perform at Wolfe Research
    03/30/21
    Fly Intel: Top five analyst upgrades
    03/30/21 Gabelli
    ViacomCBS upgraded to Buy from Hold at Gabelli
    VIACA ViacomCBS
    $44.29 /

    +1.24 (+2.88%)

    VIAC ViacomCBS
    $39.32 /

    +0.11 (+0.28%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    SNE Sony
    /

    +

    LGF.A Lionsgate
    $16.04 /

    +0.105 (+0.66%)

    DIS Disney
    $187.28 /

    +1.42 (+0.76%)

    CMCSA Comcast
    $55.11 /

    +0.97 (+1.79%)

    • 06
      Apr
    • 29
      Mar
    • 24
      Mar
    VIACA ViacomCBS
    $44.29 /

    +1.24 (+2.88%)

    VIAC ViacomCBS
    $39.32 /

    +0.11 (+0.28%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    SNE Sony
    /

    +

    LGF.A Lionsgate
    $16.04 /

    +0.105 (+0.66%)

    DIS Disney
    $187.28 /

    +1.42 (+0.76%)

    CMCSK Comcast
    $58.00 /

    + (+0.00%)

    CMCSA Comcast
    $55.11 /

    +0.97 (+1.79%)

    VIACA ViacomCBS
    $44.29 /

    +1.24 (+2.88%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    SNE Sony
    /

    +

    LGF.A Lionsgate
    $16.04 /

    +0.105 (+0.66%)

    CMCSK Comcast
    $58.00 /

    + (+0.00%)

    CMCSA Comcast
    $55.11 /

    +0.97 (+1.79%)

    VIAC ViacomCBS
    $39.32 /

    +0.11 (+0.28%)

    T AT&T
    $29.95 /

    +0.195 (+0.66%)

    SNE Sony
    /

    +

    DIS Disney
    $187.28 /

    +1.42 (+0.76%)

    CMCSA Comcast
    $55.11 /

    +0.97 (+1.79%)

    Conference/Events
    Advance Auto Parts to hold a virtual meeting » 17:12
    04/18/21
    04/18
    17:12
    04/18/21
    17:12
    AAP

    Advance Auto Parts

    $192.78 /

    +3.38 (+1.78%)

    Analyst and Investor…

    Analyst and Investor Virtual Strategy Update 2021 will be held on April 20 at 10 am. Webcast Link

    ShowHide Related Items >><<
    AAP Advance Auto Parts
    $192.78 /

    +3.38 (+1.78%)

    AAP Advance Auto Parts
    $192.78 /

    +3.38 (+1.78%)

    04/16/21 Wedbush
    Advance Auto Parts price target raised to $210 from $180 at Wedbush
    03/26/21 Stephens
    Advance Auto Parts price target raised to $180 from $175 at Stephens
    03/17/21 Wells Fargo
    Advance Auto Parts price target raised to $185 from $165 at Wells Fargo
    03/17/21 UBS
    Advance Auto Parts price target raised to $210 from $195 at UBS
    AAP Advance Auto Parts
    $192.78 /

    +3.38 (+1.78%)

    AAP Advance Auto Parts
    $192.78 /

    +3.38 (+1.78%)

    Conference/Events
    Morgan Stanley CRE analyst to hold an analyst/industry conference call » 16:46
    04/18/21
    04/18
    16:46
    04/18/21
    16:46

    Head of US CRE Research…

    Head of US CRE Research Hill, along with James Woodwell, VP of Mortgage Bankers Association, discuss the state of the Commercial Real Estate Industry on an Analyst/Industry conference call to be held on April 19 at 1 pm.

    Conference/Events
    Morgan Stanley sustainability analyst holds analyst/industry conference call » 16:33
    04/18/21
    04/18
    16:33
    04/18/21
    16:33

    Global Head of…

    Global Head of Sustainability Research Alsford, along with Harry Grocott, Fo-Founder of Treeconomy, discuss th e decarbonization puzzle on an Analyst/Industry conference call to be held on April 19 at 9 am.

    Conference/Events
    Morgan Stanley cross-asset strategists hold analyst/industry conference call » 16:30
    04/18/21
    04/18
    16:30
    04/18/21
    16:30

    Cross-Asset Strategist…

    Cross-Asset Strategist Sheets, US and European Credit Strategist Sankaran, US IG and Credit Derivatives Strategist Patkar discuss is credit still an early cycle on an Analyst/Industry conference call to be held on April 19 at 9 am.

    Upgrade
    Sensata upgraded to Outperform from In Line at Evercore ISI » 16:27
    04/18/21
    04/18
    16:27
    04/18/21
    16:27
    ST

    Sensata

    $58.53 /

    +0.14 (+0.24%)

    Evercore ISI analyst Amit…

    Evercore ISI analyst Amit Daryanani upgraded Sensata to Outperform from In Line with a price target of $67, up from $60. Given its focus on helping customers transition to "an electrified future" for auto and heavy vehicle and off road markets, Sensata looks well positioned for outsized growth, Daryanani tells investors in a research note. The stock's recent underperformance and limited multiple expansion leaves room for upside, added the analyst.

    ShowHide Related Items >><<
    ST Sensata
    $58.53 /

    +0.14 (+0.24%)

    ST Sensata
    $58.53 /

    +0.14 (+0.24%)

    04/15/21 Barclays
    Sensata price target raised to $70 from $65 at Barclays
    04/08/21 Morgan Stanley
    NXP downgraded at Morgan Stanley with growth drivers priced in
    03/22/21 Morgan Stanley
    Sensata price target raised to $72 from $68 at Morgan Stanley
    03/02/21 JPMorgan
    Sensata upgraded to Overweight at JPMorgan on auto electrification/connectivity
    ST Sensata
    $58.53 /

    +0.14 (+0.24%)

    ST Sensata
    $58.53 /

    +0.14 (+0.24%)

    Conference/Events
    Jefferies alternative energy/solar analyst hold analyst/industry conference call » 16:13
    04/18/21
    04/18
    16:13
    04/18/21
    16:13
    SPWR

    SunPower

    $27.36 /

    +0.92 (+3.48%)

    , FSLR

    First Solar

    $80.15 /

    +3.02 (+3.92%)

    , RWE

    Renewable Energy

    /

    +

    Analysts, along with Cary…

    Analysts, along with Cary Hayes, Americas President for REC Group, discuss the current state and outlook of the solar market, with a particular focus on solar modules on an Analyst/Industry conference call to be held on April 19 at 10 am.

    ShowHide Related Items >><<
    SPWR SunPower
    $27.36 /

    +0.92 (+3.48%)

    FSLR First Solar
    $80.15 /

    +3.02 (+3.92%)

    SPWR SunPower
    $27.36 /

    +0.92 (+3.48%)

    03/22/21 Goldman Sachs
    SunPower downgraded to Neutral from Buy at Goldman Sachs
    03/16/21 Morgan Stanley
    Morgan Stanley says proposed California rules 'skew negative' for rooftop solar
    03/16/21 Barclays
    SunPower price target raised to $28 from $17 at Barclays
    03/09/21 Piper Sandler
    SunPower price target lowered to $31 from $35 at Piper Sandler
    FSLR First Solar
    $80.15 /

    +3.02 (+3.92%)

    03/09/21 Piper Sandler
    First Solar price target lowered to $81 from $92 at Piper Sandler
    03/08/21
    Fly Intel: Top five analyst upgrades
    03/08/21 JPMorgan
    First Solar price target lowered to $94 from $100 at JPMorgan
    03/08/21 Credit Suisse
    First Solar upgraded to Neutral from Underperform at Credit Suisse
    RWE Renewable Energy
    /

    +

    SPWR SunPower
    $27.36 /

    +0.92 (+3.48%)

    FSLR First Solar
    $80.15 /

    +3.02 (+3.92%)

    • 15
      Dec
    • 17
      Sep
    SPWR SunPower
    $27.36 /

    +0.92 (+3.48%)

    SPWR SunPower
    $27.36 /

    +0.92 (+3.48%)

    FSLR First Solar
    $80.15 /

    +3.02 (+3.92%)

    SPWR SunPower
    $27.36 /

    +0.92 (+3.48%)

    FSLR First Solar
    $80.15 /

    +3.02 (+3.92%)

    Hot Stocks
    Prothena presents Phase 1 study results of PRX004 » 16:12
    04/18/21
    04/18
    16:12
    04/18/21
    16:12
    PRTA

    Prothena

    $24.87 /

    -0.835 (-3.25%)

    Prothena presented…

    Prothena presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at the American Academy of Neurology 2021 Virtual Annual Meeting. PRX004 showed favorable results as demonstrated by slowing of neuropathy progression for all 7 evaluable patients at 9 months, including improvement in neuropathy in 3 of the 7 patients, and improved cardiac systolic function for all 7 patients. In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels. For all of the evaluable patients, slowing of neuropathy progression was demonstrated by a mean change from baseline in Neuropathy Impairment Score of +1.29 points at 9 months. This compares favorably to a calculated mean change in NIS of +9.2 points at 9 months in untreated and placebo-treated patients with hereditary ATTR peripheral neuropathy based on analysis of published historical data. In addition, the change in NIS for each of these evaluable patients was more favorable than the published historical data. In this highly progressive disease, it was encouraging to see 3 of 7 patients demonstrate improvement in neuropathy with a mean change in NIS of -3.33 points at 9 months. These positive results were observed in patients with or without concomitant use of stabilizer therapy. PRX004 also demonstrated improvement in cardiac systolic function in each of the 7 evaluable patients, with a mean change in GLS of -1.21% at 9 months. For the 3 patients who improved on NIS, GLS improvement was more pronounced, with a mean change of -1.51% at 9 months. Taken together, these positive clinical findings suggest PRX004's depleter mechanism of action can result in benefits in both neuropathy and cardiac function.

    ShowHide Related Items >><<
    PRTA Prothena
    $24.87 /

    -0.835 (-3.25%)

    PRTA Prothena
    $24.87 /

    -0.835 (-3.25%)

    03/15/21 Jefferies
    Prothena price target raised to $38 from $30 at Jefferies
    02/26/21 RBC Capital
    Prothena upgraded to Outperform from Sector Perform at RBC Capital
    02/26/21 RBC Capital
    Prothena upgraded to Outperform from Sector Perform at RBC Capital
    02/12/21 Jefferies
    Jefferies upgrades 'very cheap' Prothena to Buy, doubles target to $30
    PRTA Prothena
    $24.87 /

    -0.835 (-3.25%)

    • 24
      Mar
    PRTA Prothena
    $24.87 /

    -0.835 (-3.25%)

    Hot Stocks
    Elbit Systems awarded $1.65B contract for flight training program » 16:10
    04/18/21
    04/18
    16:10
    04/18/21
    16:10
    ESLT

    Elbit Systems

    $143.14 /

    +1.2 (+0.85%)

    Elbit Systems announced,…

    Elbit Systems announced, further to the company's announcement of January 5, 2021, that it was awarded a contract valued at approximately $1.65B for the establishment and operation of the International Flight Training Center of the Hellenic Air Force, as part of an agreement between the Israeli Ministry of Defense and the Hellenic Ministry of National Defense. The contract will be performed over a period of approximately 20 years and will include price indexation. Under the contract, Elbit Systems will supply new M-346 training aircraft and will maintain the entire training fleet, comprised of dozens of M-346 and T-6 training aircraft for a period of approximately 20 years. In addition, the company will provide its latest advanced Embedded Virtual Avionics onboard the training aircraft, deliver networked flight simulators and an array of Ground-Based Training Stations as well as a command and control systems to enable efficient management of the flight training operation.

    ShowHide Related Items >><<
    ESLT Elbit Systems
    $143.14 /

    +1.2 (+0.85%)

    ESLT Elbit Systems
    $143.14 /

    +1.2 (+0.85%)

    11/18/20 Jefferies
    Elbit Systems downgraded to Hold on defense slowdown at Jefferies
    11/18/20 Jefferies
    Elbit Systems downgraded to Hold from Buy at Jefferies
    Hot Stocks
    CNH Industrial terminates On-Highway business discussions with FAW Jiefang » 16:08
    04/18/21
    04/18
    16:08
    04/18/21
    16:08
    CNHI

    CNH Industrial

    $15.98 /

    +0.3 (+1.91%)

    CNH Industrial has…

    CNH Industrial has confirmed that it is has terminated discussions with FAW Jiefang with regard to the company's On-Highway business, and is continuing to pursue its existing plans for a spin-off of these activities in early 2022. "CNH Industrial believes there are significant opportunities to develop its On-Highway business by accelerating the deployment of ever more sustainable transport solutions and infrastructure, in line with the EU's Green Deal ambitions," the company said in a statement.

    ShowHide Related Items >><<
    CNHI CNH Industrial
    $15.98 /

    +0.3 (+1.91%)

    CNHI CNH Industrial
    $15.98 /

    +0.3 (+1.91%)

    04/13/21 Deutsche Bank
    CNH Industrial price target raised to $21 from $18 at Deutsche Bank
    02/18/21 Citi
    CNH Industrial resumed with a Buy at Citi
    02/04/21 Vertical Research
    CNH Industrial upgraded to Buy from Hold at Vertical Research
    01/20/21 Vertical Research
    CNH Industrial initiated with a Hold at Vertical Research
    CNHI CNH Industrial
    $15.98 /

    +0.3 (+1.91%)

    Hot Stocks
    Amarin presents new analyses of EVAPORATE study » 16:06
    04/18/21
    04/18
    16:06
    04/18/21
    16:06
    AMRN

    Amarin

    $5.02 /

    +0.01 (+0.20%)

    Amarin announced that…

    Amarin announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17. As previously reported and published in the European Heart Journal, VASCEPA demonstrated significant, 17% regression of low attenuation plaque volume on multidetector computed tomography compared with placebo over 18 months. The Effect of Icosapent Ethyl on Changes in Coronary Plaque Morphology: EVAPORATE analyses presented at ESC Preventive Cardiology 2021 demonstrated that with administration of 4 g/day of VASCEPA on top of statin therapy, there was an observed change in plaque stability occurring at 9 months and sustained through 18 months. Of the 80 patients that were enrolled in the randomized, double-blind, placebo-controlled EVAPORATE trial, 55 patients had images that were able to be utilized for the histology-validated software. The EVAPORATE plaque morphology study used ElucidVivo, the first FDA-cleared analysis for specific tissue characterization using histopathologic correlates to assess plaque morphology characteristics, including Lipid Rich Necrotic Core, fibrous cap thickness, and intraplaque hemorrhage. Whereas with placebo LRNC increased and cap thickness decreased, both indicative of moving to a less stable phenotype, with icosapent ethyl there was a measured LRNC decrease and cap thickness increase, indicative of moving to a more stable phenotype. The primary limitation of this single coronary plaque study as identified by its investigators is its small sample size. More study is needed to more fully understand the effects of VASCEPA on coronary plaque to determine the relationship, if any, of such plaque effects on cardiovascular risk reduction.

    ShowHide Related Items >><<
    AMRN Amarin
    $5.02 /

    +0.01 (+0.20%)

    AMRN Amarin
    $5.02 /

    +0.01 (+0.20%)

    04/12/21 Piper Sandler
    New CEO at Amarin to facilitate continued growth, says Piper Sandler
    04/06/21 Piper Sandler
    Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
    02/25/21 Piper Sandler
    Amarin to have strong execution year ahead, says Piper Sandler
    02/01/21 Piper Sandler
    Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
    AMRN Amarin
    $5.02 /

    +0.01 (+0.20%)

    AMRN Amarin
    $5.02 /

    +0.01 (+0.20%)

    AMRN Amarin
    $5.02 /

    +0.01 (+0.20%)

    AMRN Amarin
    $5.02 /

    +0.01 (+0.20%)

    Get Full Fly Access

    Breaking market intelligence sent straight to you
    Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
    Up-to-date information on important industry events
    Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
    News focused on the companies in your portfolio
    Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.